Global Infectious Diseases Partnering 2010-2016: Deal Trends, Players and Financials Analysis

Feb 04, 2016, 07:10 ET from Research and Markets


DUBLIN, Feb. 4, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/4zn8xp/global_infectious) has announced the addition of the "Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials" company profile to their offering.

Global Infectious Diseases Partnering 2010 to 2016 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Global Infectious Diseases Partnering 2010 to 2016 includes:

  • Trends in Infectious Diseases dealmaking in the biopharma industry since 2010
  • Analysis of Infectious Diseases deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Infectious Diseases deal contract documents
  • Comprehensive access to over 3500 Infectious Diseases deal records
  • The leading Infectious Diseases deals by value since 2010
  • Most active Infectious Diseases dealmakers since 2010

In Global Infectious Diseases Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking

Chapter 3 - Financial deal terms for Infectious Diseases partnering

Chapter 4 - Leading Infectious Diseases deals and dealmakers

Chapter 5 - Infectious Diseases contract document directory

Chapter 6 - Infectious Diseases dealmaking by therapeutic target

For more information visit http://www.researchandmarkets.com/research/4zn8xp/global_infectious

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com